for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lee's Pharmaceutical Holdings Limited

0950.HK

Latest Trade

3.80HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.67

 - 

6.82

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.80
Open
--
Volume
--
3M AVG Volume
13.66
Today's High
--
Today's Low
--
52 Week High
6.82
52 Week Low
3.67
Shares Out (MIL)
588.84
Market Cap (MIL)
2,237.57
Forward P/E
1.84
Dividend (Yield %)
1.61

Next Event

Q3 2021 Lee's Pharmaceutical Holdings Ltd Earnings Release

Latest Developments

更多

Lee's Pharmaceutical Obtained Approval From CDE Of China's NMPA For Socazolimab

Lee's Pharmaceutical Reports Qtrly Profit Attributable of HK$2.11 Bln

Lee's Pharmaceutical Holdings Ltd Sees Increase In Net Profit Attributable Six Months

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lee's Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in the development, manufacture, marketing and sales of pharmaceutical products. The Company operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The Company mainly operates businesses in China and Hong Kong.

Industry

Major Drugs

Contact Info

Unit 110-111, Bio-Inf. Centre,

No.2 Science Park West Avenue,

Hong Kong Science Park, Shatin

Hong Kong

+852.null.23141282

http://www.leespharm.com

Executive Leadership

Siu Fong Lee

Executive Chairman of the Board

Lin Tom

President, Chief Operating Officer of CVie International Limited

Wanee Leelalertsuphakun

Managing Director, Chief Marketing & Sales Officer, Executive Director

Lit-Fui Lau

General Manager of Shanghai branch of Zhaoke

Dingwen Li

Director of Human Resources

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

1.1K

2019

1.2K

2020

1.2K

2021(E)

1.3K
EPS (HKD)

2018

0.703

2019

0.212

2020

0.220

2021(E)

2.060
Price To Earnings (TTM)
1.02
Price To Sales (TTM)
1.80
Price To Book (MRQ)
0.63
Price To Cash Flow (TTM)
1.01
Total Debt To Equity (MRQ)
5.02
LT Debt To Equity (MRQ)
0.30
Return on Investment (TTM)
69.45
Return on Equity (TTM)
52.60

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up